| 2.18 0.23 (11.79%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.76 |
1-year : | 3.23 |
| Resists | First : | 2.36 |
Second : | 2.76 |
| Pivot price | 1.86 |
|||
| Supports | First : | 1.86 |
Second : | 1.55 |
| MAs | MA(5) : | 2 |
MA(20) : | 1.86 |
| MA(100) : | 2.14 |
MA(250) : | 2.12 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 91.7 |
D(3) : | 86.2 |
| RSI | RSI(14): 60.4 |
|||
| 52-week | High : | 7.13 | Low : | 0.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PROK ] has closed Bollinger Bands are 1.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.19 - 2.21 | 2.21 - 2.22 |
| Low: | 1.95 - 1.97 | 1.97 - 1.98 |
| Close: | 2.16 - 2.18 | 2.18 - 2.2 |
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Fri, 17 Apr 2026
ProKidney (NASDAQ:PROK) Stock Price Up 9% - Should You Buy? - MarketBeat
Fri, 17 Apr 2026
Executive pay, governance on agenda at ProKidney (NASDAQ: PROK) vote - Stock Titan
Thu, 16 Apr 2026
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Mon, 13 Apr 2026
ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - Time to Buy? - MarketBeat
Tue, 31 Mar 2026
What Makes ProKidney Corp. (PROK) So Attractive - Yahoo Finance
Wed, 25 Mar 2026
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 142 (M) |
| Held by Insiders | 9.367e+007 (%) |
| Held by Institutions | 25.3 (%) |
| Shares Short | 16,210 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.5843e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -20 % |
| Return on Assets (ttm) | 306.2 % |
| Return on Equity (ttm) | -26.6 % |
| Qtrly Rev. Growth | 893000 % |
| Gross Profit (p.s.) | 108.94 |
| Sales Per Share | -23.99 |
| EBITDA (p.s.) | 496111 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -120 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.1 |
| Price to Cash Flow | -0.56 |
| Dividend | 0 |
| Forward Dividend | 1.533e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|